Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen, HTG Molecular Begin Second CDx Development Project

NEW YORK (GenomeWeb) – Qiagen and HTG Molecular Diagnostics have agreed to a second development program under their previously announced master assay development, commercialization, and manufacturing agreement.

As part of the program announced today, HTG Molecular and Qiagen Manchester, a wholly owned subsidiary of Qiagen, will use HTG EdgeSeq technology to develop gene expression profiling assays for use with next-generation sequencing technology to support an unnamed pharmaceutical company's therapeutic development and commercialization programs.

"We are very pleased with the early results of our partnership with Qiagen and are encouraged by customer reception to our joint capabilities, which provide a complete NGS solution from biomarker development to full companion diagnostic commercialization," HTG President and CEO TJ Johnson said in a statement.

"With two new programs realized from the Qiagen partnership to date, HTG now has three distinct clinical assay development programs underway, including two that we believe could lead to regulatory filings for companion diagnostics during 2018," Johnson added.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.